Cargando…
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma
Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the...
Autores principales: | Bydoun, Moamen, Sterea, Andra, Liptay, Henry, Uzans, Andrea, Huang, Weei‐Yuarn, Rodrigues, Gloria J., Weaver, Ian C.G., Gu, Hong, Waisman, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210040/ https://www.ncbi.nlm.nih.gov/pubmed/30009399 http://dx.doi.org/10.1002/1878-0261.12356 |
Ejemplares similares
-
A novel mechanism of plasminogen activation in epithelial and mesenchymal cells
por: Bydoun, Moamen, et al.
Publicado: (2018) -
Author Correction: A novel mechanism of plasminogen activation in epithelial and mesenchymal cells
por: Bydoun, Moamen, et al.
Publicado: (2020) -
Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10
por: Madureira, Patricia A., et al.
Publicado: (2016) -
Annexin A2 Heterotetramer: Structure and Function
por: Bharadwaj, Alamelu, et al.
Publicado: (2013) -
Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
por: Li, Yan, et al.
Publicado: (2022)